Prices re-read October 15, 2026Methodology v4.1How we score →
Compare Providers
Home / Microdosing / Microdose semaglutide: evidence and reality
This article is educational and does not replace medical advice. Prescription medication requires review by a licensed clinician and, when appropriate, a valid prescription. Compounded medications are not FDA-approved, and the FDA does not verify their safety, effectiveness or quality before marketing. Treatment eligibility is an individual clinical decision.

Released: ·Last reviewed: ·Methodology v4.1

Researched By
Medical Researcher · Western University of Health Sciences
Last medically reviewed: August 4, 2026 · This page is informational and does not constitute medical advice.
This page is maintained. Prices are re-read at source and dated; evidence is checked against the published trial. Newest across the site: news · research · corrections.

Microdose semaglutide: evidence and reality

Quick answer

"Microdose" semaglutide means using doses below the standard label schedule. It is not an FDA-approved protocol, and rigorous evidence for below-label regimens is limited. Any low-dose approach should be clinician-directed, not self-managed.

What it means

Below-label dosing, often marketed for gentler side effects or maintenance. The term is a marketing convention, not a defined medical protocol.

The evidence

Pivotal trials used specific escalation schedules. Evidence for the efficacy of deliberately low 'microdose' regimens is limited; benefits and risks are individual.

Frequently asked questions

Does microdose semaglutide work?

Evidence for below-label 'microdosing' is limited. Some patients use lower doses under clinician direction, but it is not a proven standardized protocol.

Sources

  1. U.S. Food and Drug Administration — labels and safety communications.
  2. Peer-reviewed clinical trials cited above.
  3. Our methodology and medical review policy.

Spotted an error? Submit a correction.

How the dates on this page work. Manufacturer self-pay prices were re-read on 15 October 2026: NovoCare’s Wegovy page and Lilly’s Zepbound savings page. Foundayo prices are carried from LillyDirect pages archived 25 September 2026, because lilly.com blocked automated reads. Figures captured from telehealth provider websites carry the date we read that provider’s page, which may be earlier; where it is, the row or a dated notice says so. We do not restamp a figure we have not re-read.